Rationale: Pathological increases in cardiac afterload result in myocyte hypertrophy with changes in myocyte electrical and mechanical phenotype. Remodeling of contractile and signaling Ca 2+ occurs in pathological hypertrophy and is central to myocyte remodeling. STIM1 (stromal interaction molecule 1) regulates Ca 2+ signaling in many cell types by sensing low endoplasmic reticular Ca 2+ levels and then coupling to plasma membrane Orai channels to induce a Ca 2+ influx pathway. Previous reports suggest that STIM1 may play a role in cardiac hypertrophy, but its role in electrical and mechanical phenotypic alterations is not well understood.
Objective: To define the contributions of STIM1-mediated Ca 2+ influx on electrical and mechanical properties of normal and diseased myocytes, and to determine whether Orai channels are obligatory partners for STIM1 in these processes using a clinically relevant large animal model of hypertrophy.
Methods and Results:
Cardiac hypertrophy was induced by slow progressive pressure overload in adult cats.
Hypertrophied myocytes had increased STIM1 expression and activity, which correlated with altered Ca 2+ -handling and action potential (AP) prolongation. Exposure of hypertrophied myocytes to the Orai channel blocker BTP2 caused a reduction of AP duration and reduced diastolic Ca 2+ spark rate. BTP2 had no effect on normal myocytes. Forced expression of STIM1 in cultured adult feline ventricular myocytes increased diastolic spark rate and prolonged AP duration. STIM1 expression produced an increase in the amount of Ca 2+ stored within the sarcoplasmic reticulum and activated Ca 2+ /calmodulin-dependent protein kinase II. STIM1 expression also increased spark rates and induced spontaneous APs. STIM1 effects were eliminated by either BTP2 or by coexpression of a dominant negative Orai construct. July 7, 2017 is an independent predictor of hospitalization and sudden cardiac death. 14, 15 The molecular basis of altered contractile and hypertrophic signaling [Ca 2+ ] are still not fully understood and are the topic of this study. 7 Here, we specifically study the role of the SR protein, STIM1 (stromal interaction molecule 1), and its sarcolemmal partner protein Orai in the development of electrical and contractile remodeling of adult ventricular myocytes after pressure overload. There is some evidence from previous reports that these proteins are present in cardiac myocytes and their abundance increases in disease states. 16, 17 This increase has been linked to maladaptive cardiac hypertrophy. 18, 19 However, the consequence of STIM-mediated Ca 2+ influx on the function of hypertrophied cardiac myocytes is not clearly defined, especially in large animals with Ca 2+ regulation similar to the human heart. In this study, we explore the idea that alterations in the electrical and mechanical properties of the hypertrophied heart involve STIM-dependent Ca 2+ entry and blocking this influx pathway can improve these disturbances.
STIM and Orai proteins are widely known as the key mediators of store-operated Ca 2+ entry (SOCE), a nearly ubiquitous process in nonexcitable cells. 20, 21 In mammals, there are 2 isoforms of STIM (STIM1 and STIM2) that are present in the endoplasmic reticulum (ER), 22 and 3 homologs of Orai (Orai1, Orai2, and Orai3) are located in the plasma membrane. SOCE occurs during periods of ER Ca 2+ depletion, which can physiologically occur after inositol triphosphate receptor activation of ER Ca 2+ release. STIM senses reduced ER [Ca 2+ ] via a luminal ejection fraction-hand motif and subsequently undergoes a conformational change resulting in oligomerization. 23 Activated STIM proteins are then able to bind and gate Orai channels located in the plasma membrane, which are highly selective, low-conductance Ca 2+ channels. 24 The resulting Ca 2+ influx adds Ca 2+ to the ER and is also thought to activate Ca 2+ -dependent signaling processes. 25 Cardiac myocytes have robust Ca 2+ entry through the L-type Ca 2+ channel with each heartbeat. This Ca 2+ influx induces Ca 2+ release from the SR to initiate contraction and also provides Ca 2+ to load the SR 26 . The SR releases and takes up Ca 2+ with each heartbeat and is never depleted during normal physiological function. It is, therefore, not surprising that a physiological role for STIM and Orai in cardiac myocytes has not been defined. Yet, many independent groups have found STIM1 to be present in cardiac myocytes 18 although there are conflicting reports on the function of STIM1 and SOCE in these cells. 16, 27, 28 In the diseased heart, SR Ca 2+ regulation is altered 11 and increased SOCE activity has been observed in rodent cardiac disease models. Some groups have linked this increased activity with pathological hypertrophy. A recent study 16 in diseased ventricular myocytes. However, this hypothesis has not been tested in a clinically relevant large animal model.
The objective of our study was to explore the if/how STIM1 contributes to the changes in electrical and contractile phenotype of hypertrophied ventricular myocytes from the adult feline heart. We used the feline model because, unlike rodent models, it has electrical and Ca 2+ regulatory properties that are similar to those of human. 29, 30 Our experiments tested the hypothesis that in myocytes with hypertrophy from persistent pressure overload, SR-based STIM1 is activated and partners with surface membrane Orai to produce Ca 2+ entry that contributes to their altered phenotype. Our results support the idea that STIM1 and Orai are expressed, but do not contribute to the electromechanical function of the healthy heart. In hypertrophied myocytes, STIM1 becomes activated and induces Ca 2+ entry after associating with Orai, resulting in enhanced SR loading and AP prolongation. Excessive STIM1-mediated Ca 2+ entry caused Ca 2+ sparks, spontaneous APs, and cell death. These results suggest that STIM1 activation in disease might help preserve SR Ca 2+ load but predisposes myocytes to arrhythmias and death.
Methods
Methods are described in detail in the Online Data Supplement. Briefly, LV hypertrophy was induced in young cats by aortic banding and myocytes were isolated using collagenase as described in detail previously. After isolation, Ca 2+ transients, Ca 2+ currents, Ca 2+ sparks, and cell shortening were measured using standard techniques described in detail in previous reports from our group. 27, 31 Isolated myocytes from control and banded animals were exposed to 1 µmol/L BTP2 (N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide), in vitro, in cell physiology experiments. Myocytes were also studied in the primary culture and infected with adenovirus overnight, as described previously. 32 Experiments with these myocytes were completed within 36 hours of isolation to minimize effects of culture-dependent phenotypic drift.
33,34

Results
Pressure Overload Hypertrophy Is Associated With Increased STIM1 Expression and Activity
Slow progressive pressure overload was induced by aortic banding of young animals, to induce LV hypertrophy, similar to our previous reports. 35, 36 This procedure caused significant increases in systolic proximal aortic pressure after 4 months (proximal versus distal pressure: 149.8±15.3 versus 87±9.6 mm Hg; Figure 1A ) and a systolic pressure gradient of 63 mm Hg across the aortic constriction. There are no significant decreases in echocardiogram-derived systolic function in this model ( Figure 1B ). Enddiastolic wall thickness was significantly increased by banding as measured by echocardiography (banded versus sham: 7.5±0.5 versus 4.6±0.3 mm; P≤0.05; Figure 1C ). The heart weight/body weight ratio was significantly increased in banded versus sham animals (9.2±1.13 versus 4.6±0.4; P≤0.01; Figure 1D ).
Pressure overload was associated with increases in the expression of SOCE-related mRNA. Real-time polymerase chain reaction was used to measure mRNA levels of SOCE proteins in mRNA from isolated myocytes. Myocytes from banded animals had significantly greater amounts of STIM1 and Orai3 mRNA and nonsignificant increases in STIM2 and Orai1 mRNA ( Figure 1E ). Orai2 was not detected in normal or hypertrophied feline myocytes.
Immunofluorescence staining of isolated myocytes showed that STIM1 exhibited a striated fashion in control myocytes ( Figure 1F , top), with what appeared to be uniform intensity along the striations. Co-staining with actinin suggests that STIM1 is localized near the Z-line, where the sarcolemma/SR dyad resides (Online Figure IA) . This staining pattern is similar to that seen by others. 16 Hypertrophied myocytes from banded animals exhibited a more uneven STIM1 intensity, with a punctate pattern ( Figure 1F , bottom). The mean fluorescence intensity of STIM1 staining was increased in banded animals ( Figure 1G ). STIM1 protein, measured by Western analysis, was also increased in hypertrophied versus normal hearts (Online Figure IB) . Collectively, these studies show that STIM1 expression increases in feline ventricular myocytes with pressure overload-induced hypertrophy and suggest that STIM1 may oligomerize in these myocytes.
STIM1-Orai Contributes to Altered Ca 2+ Handling in Hypertrophied Myocytes
We have previously shown changes in contractile Ca 2+ regulation in the hypertrophied feline ventricular myocytes, [37] [38] [39] which are consistent with the modifications in Ca 2+ handling observed by other laboratories. 11, 40 In the present study, we found that myocytes from banded animals had Ca
2+
-handling alterations consistent with previous reports, which includes reduced contraction magnitude, slowing of the systolic Ca The contribution of STIM1-Orai-dependent Ca 2+ influx to steady-state myocyte contractions and Ca 2+ transients was first explored by exposing isolated myocytes to the Orai blocker BTP2. This antagonist was chosen for its relative specificity for Orai over other ion channels. 41 Myocytes were incubated with either vehicle or BTP2 and then paced at 1 Hz to measure steady-state fractional shortening and Ca 2+ transients. BTP2 did not significantly affect systolic Ca 2+ transients or contractions in either normal (Online Figure II) or hypertrophied myocytes (Figure 2A through 2I). However, BTP2 did cause an increase in diastolic sarcomere length in hypertrophied myocytes ( Figure 2J ).
The effects of BTP2 on AP duration (APD) in sham and hypertrophied myocytes were determined using the voltage-sensitive dye di-8-anneps. This method is technically less demanding than patch clamp approaches and allows for study of an increased number of myocytes. In addition, this approach allowed for evaluation of AP waveform, without dialysis that could eliminate distinct intracellular contents in hypertrophied myocytes. Preliminary studies showed that APs had similar waveforms and durations when recorded using either di-8-anneps or patch clamp in myocytes (not shown). BTP2 had no effect on APD in sham myocytes, with a time to 90% repolarization of 285±9.5 July 7, 2017 ms ( Figure 3 ). In contrast, myocytes from banded animals had longer baseline APDs and had significant APD shortening when incubated with BTP2, as compared with vehicle controls (time to 90% APD: 434±11 versus 390±11.5 ms for vehicle and BTP2, respectively; P≤0.01; Figure 3) . In separate experiments, we found that BTP2 did not reduce Ca 2+ current at the concentrations used in these experiments (Online Figure IIK) . Ca 2+ sparks were quantified during the diastolic interval (1 Hz) in sham and hypertrophied myocytes. Sparks were infrequently observed in sham myocytes but were routinely found in hypertrophied myocytes. BTP2 significantly reduced the number of sparks in hypertrophied myocytes as compared with vehicle control (Figure 4 ).
Increasing STIM1 Induces Ca 2+ Influx That Loads the SR
To further explore the contribution of increased STIM1 expression to altered myocyte Ca 2+ regulation in disease, adenoviral gene transfer was used to express STIM1 (human cDNA clone) or RFP (red fluorescent protein) in freshly isolated adult feline myocytes (AFMs). Western blot and immunofluorescence confirmed increased expression of STIM1 within 12 to 18 hours of infection (Online Figure III) . In these studies, STIM1 was found to be organized into puncta, similar to the staining pattern seen in hypertrophied myocytes.
AFMs and other myocytes from large mammals are electrically and mechanically quiescent in primary culture, and they maintain low cytoplasmic and SR Ca 2+ . 27 ] when not paced (Online Figure IVA and IVB) . 30 These features are distinct from the conditions in rodent myocytes where high cytosolic [Na + ] leads to persistent cytosolic and SR Ca 2+ overload. 30 Unpaced AFMs with STIM1 expression exhibited higher SR loads than RFP myocytes (Online Figure  IVA and IVB). When paced, STIM1 myocytes had significantly increased Ca 2+ transient amplitudes and decreased diastolic sarcomere lengths but increases in fractional myocyte failed to achieve statistical significance ( Figure 5A through 5E ). A, Proximal and distal pressures and the difference (Δsys) across the aortic band after 4 mo, measured using a pressure catheter (n=4). B, Fractional shortening measured by echocardiography over 4 mo (n=4 each group). C, End-diastolic wall thickness measured by echocardiography over 4 mo (n=4 each group). D, Heart weight/body weight ratio (HW/BW) in sham and banded animals (n=4 each group). E, mRNA levels were measured by real-time-polymerase chain reaction in myocytes isolated from sham and banded animals after 4 mo, normalized by GAPDH expression (n=4 each group). F, Transmitted light and STIM1 immunofluorescence staining in isolated myocytes from sham and banded animals. Scale bar=25 µm. G, The average fluorescence intensity of myocytes stained for STIM1 (n=4 animals each group, 38-42 myocytes). *P≤0.05 vs sham, **P≤0.01 vs sham, ***P≤0.001 vs sham, #P≤0.001 vs baseline, ##P≤0.0001 vs baseline). STIM1 could interact with a variety of sarcolemmal proteins to induce increased Ca 2+ entry. 23 Our results suggest that STIM1 interaction with Orai is the pathway for Ca 2+ entry in unpaced myocytes that enhances diastolic SR Ca 2+ loading. However, previous studies suggest that STIM1 can also directly interact with the L-type calcium channel (LTCC) and modify its behavior, 42, 43 and this could alter myocyte Ca 2+ . To test whether STIM1 interacted with LTCCs to alter SR loading, we exposed unpaced AFMs±STIM1 to verapamil, a potent LTCC blocker, and then induced SR Ca 2+ release. Verapamil did not affect SR load in unpaced STIM1-expressing myocytes (Online Figure IVA and IVB) . Furthermore, we found that STIM1 expression did not alter LTCC current density, either at basal levels or after BAYK8644 treatment (Online Figure  IVC) . However, STIM1-infected cells with increased Ca 2+ transients had greater Na + /Ca 2+ exchange activity (Online Figure IVD) .
It has been recently suggested that 1 function of STIM1 in cardiac myocytes is to interact with PLB to enhance the activity of SERCA. We attempted to replicate this interaction by coimmunoprecipitating STIM1 with PLB. No interaction between STIM1 and PLB was found. We did observe SERCA2a immunoprecipitate with PLB, as expected 44 (Online Figure  V) . These results indicate that STIM1 does not interact with PLB in feline myocytes and suggest that effects of STIM1 on Ca 2+ influx are due to its interaction with sarcolemmal Orai channels. Increased STIM1 Expression Is Sufficient to Induce Diastolic Sparks STIM1-and RFP-expressing myocytes were paced, and diastolic Ca 2+ sparks and sarcomere length were measured. A low rate of spark activity was observed in RFP control myocytes ( Figure 5F and 5G). STIM1 myocytes exhibited increased spark rates and a greater reduction in diastolic sarcomere length ( Figure 5E ). These changes mirrored the increased spark activity and reduced sarcomere length seen during diastole in myocytes from banded animals ( Figure 4 ). BTP2 sparks, an Orai construct with a mutation in its pore-forming region (E106Q) that blocks Ca 2+ permeation was used. 45 This mutant will oligomerize with endogenous Orai channels (all isoforms), causing a dominant negative (dn-Orai) effect, blocking all Orai channel activity. 45 AFMs were infected with dn-Orai that was tagged with RFP, along with STIM1. These experiments showed that STIM1 was colocalized with dnOrai in a punctated pattern along the sarcolemma ( Figure 5H ). Coexpression of dn-Orai with STIM1 prevented the increased diastolic spark rate caused by STIM1 alone (Figure 5F and 5G). Collectively, these results suggest that Orai is a necessary partner for STIM1 to cause Ca 2+ influx in AFMs.
STIM1-Orai-Mediated Ca 2+ Influx Causes Ca
2+
Sparks and APs.
AFMs expressing STIM1 exhibit spontaneous Ca 2+ sparks and spontaneous contractions (Online Movie I), whereas control myocytes were quiescent (Online Movie II). To explore the bases of these spontaneous contractions, we monitored membrane voltage using di-8-anneps. These experiments showed that STIM1-expressing myocytes demonstrate diastolic depolarization preceding spontaneous APs and contractions ( Figure 6A ), and these depolarizations are associated with spontaneous SR Ca 2+ release. BTP2 treatment of STIM1-expressing myocytes blocked spontaneous APs and shortened the APD of paced myocytes ( Figure 6B and 6C) . These results are consistent with the idea that increased STIM1 expression produces Ca 2+ influx through Orai, increasing SR Ca 2+ loading that eventually results in spontaneous SR Ca 2+ release (sparks). Spontaneous SR Ca 2+ release is known to induce Na + /Ca 2+ exchanger-mediated inward current that can be sufficient to depolarize the membrane potential and trigger an AP 40 . These experiments also show that Ad-STIM1-infected AFMs could have sufficient numbers of Ca 2+ sparks to elicit spontaneous APs ( Figure 6A ). Spontaneous Ca 2+ sparks were not blocked by verapamil, confirming that STIM1 does not raise myocyte Ca 2+ levels by altering the activity of LTCCs ( Figure 6D and 6E). BTP2 and dn-Orai blocked resting sparks and spontaneous AP generation ( Figure 6D and 6E). Our experiments showed that STIM1 expression increased the rate of AFM death after 72 hours (20%-40% viability) versus RFP-infected controls (80%-90% viability; Figure 7A and 7B). We next explored the STIM1 membrane signaling partner that is responsible for Ca 2+ influx and cell death signaling in STIM1-infected AFMs. Our group and others have documented previously the importance of canonical transient receptor potential channels (TRPC)-mediated Ca 2+ influx in cell death signaling myocytes. 27, 46 Some reports suggest that STIM1 can bind to and activate TRPC channels and induce Ca 2+ influx. 47 Previous study in our laboratory demonstrated that expression of a dominant negative TRPC4 construct (dn-TRPC4) results in total inhibition of all TRPC activity, through its oligomerization with each of the endogenous TRPC isoforms. 27 Using this same construct, we compared the effects of coinfection of STIM1-infected AFMs with either dn-TRPC4 27 or dn-Orai. STIM1-induced cell death was not altered by dn-TRPC4 but was eliminated by dn-Orai ( Figure 7B ). BTP2 also rescued the cell death phenotype of STIM1 myocytes ( Figure 7B ).
The link between increased Ca 2+ influx and cell death signaling has also been shown to involve the activation of Ca 2+ / calmodulin-dependent protein kinase II (CaMKII). 48 To test this idea, STIM1 or RFP-infected myocytes were treated with KN-93, a CaMKII inhibitor. KN-93 rescued myocytes from cell death although not as completely as with BTP2 ( Figure 7C ).
Collectively, these results indicate that increased STIM1-mediated Ca 2+ entry can activate CaMKII, which likely contributes to both cell death and changes in myocyte Ca 2+ handling. Additional evidence for this idea was that PLB phosphorylation at threonine 17 (a CaMKII-specific site) was found to be increased in STIM1 myocytes ( Figure 7D ). PLB-threonine 17 phosphorylation also can explain the accelerated tau of Ca 2+ transient decay in STIM1-infected myocytes (Online Figure  IVE) . BTP2 blocked STIM1-mediated PLB-T17 phosphorylation ( Figure 7D ), consistent with a central role of Orai. No changes in CaMKII autophosphorylation at Thr-286 or Thr-287 were observed by Western blot (data not shown).
CaMKII activity has previously been shown to cause cell death by activating both apoptosis and necrosis in cardiac myocytes. 49 To determine whether STIM1 causes apoptosis, caspase 3 cleavage was measured by Western analysis. No differences were found between STIM1-expressing myocytes and RFP controls (Online Figure VI) . These results suggest that STIM1 activity can lead to necrotic cell death, similar to what we have seen when excess Ca 2+ influx through the LTCC is induced.
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Discussion
SOCE and its effector proteins-STIM and Orai-are present in many tissue types where they regulate many different processes. 23 In noncardiac cells, SOCE is activated after ER Ca 2+ depletion and the resultant Ca 2+ influx refills the ER stores. 23 The presence and functional significance of SOCE in the normal adult heart are not well defined, but STIM expression in cardiac disease has been linked to pathological cardiac hypertrophy. 18 The goal of the present study was to determine whether Ca 2+ influx through a STIM-and Orai-dependent pathway contributes to the electromechanical phenotype of either normal or hypertrophied ventricular myocytes. A novel aspect of our study was that 2 independent approaches, pharmacological (BTP2) Orai blockade and genetic (dn-Orai) manipulation were used to demonstrate phenotypic features that were dependent on Orai channel function. Our experiments showed that both STIM1/2 and Orai1/3 are expressed in normal feline myocytes but are not major contributors to the phenotypic features we measured in this study (Online Figure II) . Therefore, their function in the normal heart is yet to be defined. STIM/Orai contributions to electromechanical remodeling in hypertrophied hearts were studied in ventricular myocytes isolated from feline hearts with slow, progressive pressure overload (aortic banding). Myocytes isolated from hypertrophied hearts exhibited increased STIM1 expression, similar to previous reports. 28 Our novel findings include the observation that STIM1 was organized into puncta, indicating STIM1 activation in hypertrophied myocytes ( Figure 1F ). Blockade of ion flux through STIM1/Orai with BTP2 in hypertrophied myocytes revealed, for the first time, that STIM1/ Orai activity contributes to APD prolongation (Figure 3 ). In addition, we made the novel observation that STIM1-Orai activity leads to diastolic Ca 2+ sparks and a shortening of the diastolic sarcomere length (Figures 2 and 4) . Additional experiments with cultured AFMs showed that increasing STIM1 expression was sufficient to induce persistent Ca 2+ influx and recapitulated many of the phenotypic features of hypertrophied myocytes. Specifically, STIM1 expression-induced Ca 2+ influx caused spontaneous Ca 2+ sparks, shortening of diastolic sarcomere length, SR Ca 2+ loading, and spontaneous APs ( Figure 5 ). STIM1 expression was also linked to cell death, in part, by activating CaMKII ( Figure 7C ). Our studies with BTP2 and dn-Orai, 2 reagents that have not previously been used to investigate Ca 2+ handling in ventricular cardiac myocytes, demonstrate that Ca 2+ entry into hypertrophied ventricular myocytes through a STIM1-Orai pathway contribute to those phenotypic features of diseased myocytes that have been linked to lethal arrhythmias, contractile dysfunction, and myocyte death signaling.
Expression and Activity of STIM and Orai in Normal Cardiac Myocytes
The nature of SOCE in normal adult cardiac myocytes from a variety of species has been investigated by many laboratories and found to be small or undetectable. 16, 18, 19 However, myocyte STIM1 knockout leads to aberrant cardiac structure and function. 50 Therefore, STIM1 clearly has roles that are yet to be defined. The experiments performed in the current study support the idea that STIM-Orai activity makes little or no contribution to the electromechanical function of normal ventricular myocytes. BTP2, a potent SOCE (Orai) blocker, 23, 51 did not modify APD, Ca 2+ transients, or contractions of normal myocytes (Figures 2 and 3 ; Online Figure II ). These data suggest that STIM and Orai proteins, while present in the normal heart, have little or no effects on Ca 2+ cycling. ] stores 25 and these issues were not examined. It is also possible that STIM and Orai have functional roles in the normal heart beyond the electromechanical features that we primarily examined.
STIM-Orai Form a Ca 2+ Influx Pathway That Contributes to Electromechanical Remodeling in Hypertrophy
STIM1 expression increases after pressure overload, 18, 19, 28 and the resultant Ca 2+ influx is thought to be involved in the induction of pathological hypertrophy. STIM1 may be part of the fetal gene program that becomes reactivated during pathological stress and could contribute a pool of Ca 2+ that activates pathological hypertrophy signaling. Reduction of STIM1 levels has been shown to reduce hypertrophic signaling in both neonatal and adult rodent myocytes. 18, 19, 52 Increased expression of STIM1 conversely resulted in an exaggerated hypertrophic response to TAC, myocardial infarction, and chronic isoproterenol infusion in rodents. 28 Collectively, these studies support the idea that STIM1 expression and activity increase in myocytes responding to persistent pathological stress and the resultant response includes myocyte hypertrophy.
The direct contribution of STIM1-Orai-dependent Ca 2+ influx to the distinctive electromechanical phenotype of the hypertrophied ventricular myocytes has not been well studied and was the topic of this study. A feline model of slow progressive pressure overload that has critical features of human diseases, including concentric LV hypertrophy without systolic dysfunction (Figure 1 ), was used. This model has many features of a human condition called heart failure with preserved ejection fraction, 53, 54 with increases in ventricular wall thickness and heart weight to body weight ratio ( Figure 1C and 1D) without cardiac dilation or reductions in systolic function ( Figure 1B) . In myocytes from banded animals, STIM1 mRNA and protein were increased along with a small but significant increase in Orai3 mRNA ( Figure 1E ). It is possible that the Orai3 isoform is the major partner for STIM1 in cardiac disease, as found by others. 17 Future studies should focus on how the unique properties of Orai3 contribute to the electromechanical features of hypertrophied myocytes.
In myocytes from normal animals, immunofluorescence staining revealed that STIM1 is localized uniformly in the SR membrane along the Z-line (Online Figure I ) but in banded myocytes exhibited a punctated pattern ( Figure 1F ), indicative of STIM1 oligomerization. 25 These results support the idea that STIM1 is increased in abundance and activated in the hypertrophied heart.
A Contractile Role for STIM and Orai in Hypertrophy
Alterations in myocyte Ca 2+ handling are central to the development of the electromechanical phenotype of the diseased heart. 11 The idea that Ca 2+ entry through a STIM1-Orai complex contributes to phenotypic adaptation in disease has not, to our knowledge, been studied in detail previously, especially July 7, 2017 in animal models with electromechanical properties similar to those in the human heart. To investigate whether increased STIM1-Orai activity contributes to contractile abnormalities in feline hypertrophy, we first used BTP2 to block Orai channels. In comparison to other SOCE antagonists, BTP2 has little affinity for LTCCs 55 (Online Figure IIK) and potassium channels. 41 BTP2 had no effects on APs, Ca 2+ transients, or contractions in normal myocytes, consistent with little or no STIM1-Orai activity in the normal heart and also documenting the lack of off-target effects under the conditions we used (Online Figure II) .
The phenotypic features of hypertrophied AFMs included prolongation of the APD, slowing and prolongation of the Ca 2+ transient, reductions of diastolic sarcomere length, increases in diastolic spark rate, and prolongation of contraction (Figures 2 through 4) . These changes result from modifications in the abundance and behavior of many molecules that participate in contraction. 26 To define a contribution of STIM1-Orai in these complex adaptations, hypertrophied AFMs were treated with BTP2. These studies showed that BTP2 shortened the APD, reduced diastolic spark rates, and produced a lengthening of diastolic sarcomere length, but had no significant effects on steady-state Ca 2+ transients (Figures 2  through 4) . A major advantage of using the feline model to explore STIM-Orai contributions to APD is the low membrane conductance during their human-like AP plateau phase. 13 The high-conductance state during repolarization of rodent APs masks changes in small currents that could make important contributions to changes in APD in human disease. 12, 13 Our results suggest that BTP2 blocks a small amount of Ca 2+ entry through a STIM-Orai channel complex in hypertrophied AFMs that contributes to APD prolongation in hypertrophied AFMs. Our results also suggest that this Ca 2+ influx can contribute to diastolic SR Ca 2+ leak (Ca 2+ sparks) that can reduce diastolic sarcomere length. Collectively, these data are consistent with the idea that increased STIM1/Orai activity in hypertrophy contributes to the electromechanical phenotype of hypertrophied AFMs.
STIM1/Orai Regulate SR Ca
2+
Studies in genetically modified mice strongly support the idea that STIM1 expression is linked to cardiac hypertrophy, 19 likely through activation of SOCE. However, these studies do not directly link STIM1 to functional changes because these could be secondary to the hypertrophy rather than directly resulting from STIM1 activity. To directly link the contributions of increased STIM1 expression/activity to myocyte electromechanical properties, we acutely expressed STIM1 in cultured AFMs. This model system allowed us to manipulate levels of STIM1 with minimal compensatory changes in global gene expression, which often occurs in genetic mouse models or in any model of induced disease. STIM1 was organized into puncta (Online Figure IIIB) in STIM1-expressing AFMs, comparable to the pattern observed in myocytes from banded animals. Acute STIM1 expression caused several functional alterations that paralleled changes observed in hypertrophied feline myocytes, including Ca 2+ sparks during the diastolic period in paced myocytes (Figure 5F ), prolonged APs ( Figure 6B) , and increased Na + /Ca 2+ exchange-mediated Ca 2+ efflux (Online Figure IVD) . These alterations were reduced, both in vitro and in freshly isolated hypertrophied myocytes, when cells were treated with BTP2, supporting a direct role of STIM1-Orai. Cultured AFMs normally maintain low cytosolic and SR [Ca 2+ ]. 27 Expressing STIM1 caused an increase in SR Ca 2+ stores (Online Figure IV) ] within the diffusion limiting cleft between the T-tubule and SR membranes 40 or by altering the properties of ryanodine receptors, possibly by CaMKII-mediated phosphorylation, which we showed was increased in STIM1 myocytes. A recent study in cultured rodent ventricular myocytes suggests that expressed STIM1 interacts with PLB to alter SR Ca 2+ uptake and induce SR Ca 2+ sparks. 16 We explored this possibility by examining the interaction between PLB and STIM1 using coimmunoprecipitation approaches (Online Figure V) but could find no evidence to support this hypothesis.
STIM1 Expression Can Cause AFM Necrosis
Our in vitro studies show that STIM1 expression increased the rate of AFM death (Figure 7 ). STIM1-infected AFMs did not appear to die via apoptosis, suggestive of a necrotic process. We have previously found that persistent increases in Ca 2+ influx via the LTCC induces a necrotic cell death in genetically modified mice. 56, 57 The cell death effects of STIM1 were abolished by BTP2 and dn-Orai, documenting a role for Ca 2+ influx via the STIM-Orai complex. Activation of CaMKII was also shown to be involved in this cell death effect ( Figure 7D and 7E). These results warrant further exploration, as increased cell death in vivo would contribute to cardiac fibrosis and compensatory hypertrophy by the remaining myocytes, which may be partly responsible for the hypertrophy induced by STIM1 that others have observed. 19 In summary, the present study shows that pathological hypertrophy is associated with increases in STIM1 expression in AFMs. Our results are consistent with the idea that STIM1 associates with sarcolemmal Orai channels to produce Ca 2+ influx that prolongs the APD, helps maintain SR Ca 2+ load, but induces SR Ca 2+ leak (Ca 2+ sparks) and reduced diastolic sarcomere length. These changes likely contribute to disturbed Ca 2+ regulation, Ca
2+
-dependent arrhythmias and cell death in the diseased heart. Our findings suggest that STIM1-Orai activity increases in myocytes from hearts with disease-related increases in the contractile demands of the heart. Collectively, our findings suggest that STIM-Orai-mediated Ca 2+ influx directly contributes to both the induction of pathological hypertrophy and the aberrant electromechanical phenotype of the hypertrophied heart, making this complex an attractive therapeutic target.
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